The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Insulin Biosimilars Market Research Report 2025
Synopsis
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
The global Insulin Biosimilars market was valued at US$ 1480 million in 2023 and is anticipated to reach US$ 1856.2 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Insulin Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Biosimilars.
Report Scope
The Insulin Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Insulin Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Insulin Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Segment by Type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
Segment by Application
Type I Diabetes
Type II Diabetes
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Insulin Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Insulin Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
The global Insulin Biosimilars market was valued at US$ 1480 million in 2023 and is anticipated to reach US$ 1856.2 million by 2030, witnessing a CAGR of 3.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Insulin Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Biosimilars.
Report Scope
The Insulin Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Insulin Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Insulin Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Segment by Type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
Segment by Application
Type I Diabetes
Type II Diabetes
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Insulin Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Insulin Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Insulin Biosimilars Market Overview
1.1 Product Overview and Scope of Insulin Biosimilars
1.2 Insulin Biosimilars Segment by Type
1.2.1 Global Insulin Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 Rapid-Acting Biosimilars
1.2.3 Long-Acting Biosimilars
1.2.4 Premixed Biosimilars
1.3 Insulin Biosimilars Segment by Application
1.3.1 Global Insulin Biosimilars Market Value by Application: (2024-2030)
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Global Insulin Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Insulin Biosimilars Revenue 2019-2030
1.4.2 Global Insulin Biosimilars Sales 2019-2030
1.4.3 Global Insulin Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Insulin Biosimilars Market Competition by Manufacturers
2.1 Global Insulin Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global Insulin Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Insulin Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global Insulin Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Insulin Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Insulin Biosimilars, Product Type & Application
2.7 Insulin Biosimilars Market Competitive Situation and Trends
2.7.1 Insulin Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Insulin Biosimilars Players Market Share by Revenue
2.7.3 Global Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Insulin Biosimilars Retrospective Market Scenario by Region
3.1 Global Insulin Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Insulin Biosimilars Global Insulin Biosimilars Sales by Region: 2019-2030
3.2.1 Global Insulin Biosimilars Sales by Region: 2019-2024
3.2.2 Global Insulin Biosimilars Sales by Region: 2025-2030
3.3 Global Insulin Biosimilars Global Insulin Biosimilars Revenue by Region: 2019-2030
3.3.1 Global Insulin Biosimilars Revenue by Region: 2019-2024
3.3.2 Global Insulin Biosimilars Revenue by Region: 2025-2030
3.4 North America Insulin Biosimilars Market Facts & Figures by Country
3.4.1 North America Insulin Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Insulin Biosimilars Sales by Country (2019-2030)
3.4.3 North America Insulin Biosimilars Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Insulin Biosimilars Market Facts & Figures by Country
3.5.1 Europe Insulin Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Insulin Biosimilars Sales by Country (2019-2030)
3.5.3 Europe Insulin Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Insulin Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific Insulin Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Insulin Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific Insulin Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Insulin Biosimilars Market Facts & Figures by Country
3.7.1 Latin America Insulin Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Insulin Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America Insulin Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Insulin Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa Insulin Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Insulin Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa Insulin Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Insulin Biosimilars Sales by Type (2019-2030)
4.1.1 Global Insulin Biosimilars Sales by Type (2019-2024)
4.1.2 Global Insulin Biosimilars Sales by Type (2025-2030)
4.1.3 Global Insulin Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global Insulin Biosimilars Revenue by Type (2019-2030)
4.2.1 Global Insulin Biosimilars Revenue by Type (2019-2024)
4.2.2 Global Insulin Biosimilars Revenue by Type (2025-2030)
4.2.3 Global Insulin Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global Insulin Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global Insulin Biosimilars Sales by Application (2019-2030)
5.1.1 Global Insulin Biosimilars Sales by Application (2019-2024)
5.1.2 Global Insulin Biosimilars Sales by Application (2025-2030)
5.1.3 Global Insulin Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global Insulin Biosimilars Revenue by Application (2019-2030)
5.2.1 Global Insulin Biosimilars Revenue by Application (2019-2024)
5.2.2 Global Insulin Biosimilars Revenue by Application (2025-2030)
5.2.3 Global Insulin Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global Insulin Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi S.A.
6.1.1 Sanofi S.A. Corporation Information
6.1.2 Sanofi S.A. Description and Business Overview
6.1.3 Sanofi S.A. Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi S.A. Insulin Biosimilars Product Portfolio
6.1.5 Sanofi S.A. Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Corporation Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Boehringer Ingelheim Insulin Biosimilars Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 Eli Lilly & Co.
6.3.1 Eli Lilly & Co. Corporation Information
6.3.2 Eli Lilly & Co. Description and Business Overview
6.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lilly & Co. Insulin Biosimilars Product Portfolio
6.3.5 Eli Lilly & Co. Recent Developments/Updates
6.4 Novo Nordisk A/S
6.4.1 Novo Nordisk A/S Corporation Information
6.4.2 Novo Nordisk A/S Description and Business Overview
6.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk A/S Insulin Biosimilars Product Portfolio
6.4.5 Novo Nordisk A/S Recent Developments/Updates
6.5 Biocon
6.5.1 Biocon Corporation Information
6.5.2 Biocon Description and Business Overview
6.5.3 Biocon Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Biocon Insulin Biosimilars Product Portfolio
6.5.5 Biocon Recent Developments/Updates
6.6 Geropharm
6.6.1 Geropharm Corporation Information
6.6.2 Geropharm Description and Business Overview
6.6.3 Geropharm Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Geropharm Insulin Biosimilars Product Portfolio
6.6.5 Geropharm Recent Developments/Updates
6.7 Wockhardt
6.6.1 Wockhardt Corporation Information
6.6.2 Wockhardt Description and Business Overview
6.6.3 Wockhardt Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Wockhardt Insulin Biosimilars Product Portfolio
6.7.5 Wockhardt Recent Developments/Updates
6.8 Gan&Lee Pharmaceuticals
6.8.1 Gan&Lee Pharmaceuticals Corporation Information
6.8.2 Gan&Lee Pharmaceuticals Description and Business Overview
6.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Product Portfolio
6.8.5 Gan&Lee Pharmaceuticals Recent Developments/Updates
6.9 The United Laboratories International
6.9.1 The United Laboratories International Corporation Information
6.9.2 The United Laboratories International Description and Business Overview
6.9.3 The United Laboratories International Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 The United Laboratories International Insulin Biosimilars Product Portfolio
6.9.5 The United Laboratories International Recent Developments/Updates
6.10 Tonghua Dongbao Pharmaceutical
6.10.1 Tonghua Dongbao Pharmaceutical Corporation Information
6.10.2 Tonghua Dongbao Pharmaceutical Description and Business Overview
6.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Portfolio
6.10.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Insulin Biosimilars Industry Chain Analysis
7.2 Insulin Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Insulin Biosimilars Production Mode & Process
7.4 Insulin Biosimilars Sales and Marketing
7.4.1 Insulin Biosimilars Sales Channels
7.4.2 Insulin Biosimilars Distributors
7.5 Insulin Biosimilars Customers
8 Insulin Biosimilars Market Dynamics
8.1 Insulin Biosimilars Industry Trends
8.2 Insulin Biosimilars Market Drivers
8.3 Insulin Biosimilars Market Challenges
8.4 Insulin Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Insulin Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Insulin Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Insulin Biosimilars Market Competitive Situation by Manufacturers in 2023
Table 4. Global Insulin Biosimilars Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Insulin Biosimilars Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Insulin Biosimilars Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Insulin Biosimilars Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Insulin Biosimilars Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Insulin Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Insulin Biosimilars, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Insulin Biosimilars, Product Type & Application
Table 12. Global Key Manufacturers of Insulin Biosimilars, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Insulin Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Insulin Biosimilars as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Insulin Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Insulin Biosimilars Sales by Region (2019-2024) & (K Units)
Table 18. Global Insulin Biosimilars Sales Market Share by Region (2019-2024)
Table 19. Global Insulin Biosimilars Sales by Region (2025-2030) & (K Units)
Table 20. Global Insulin Biosimilars Sales Market Share by Region (2025-2030)
Table 21. Global Insulin Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Insulin Biosimilars Revenue Market Share by Region (2019-2024)
Table 23. Global Insulin Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Insulin Biosimilars Revenue Market Share by Region (2025-2030)
Table 25. North America Insulin Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Insulin Biosimilars Sales by Country (2019-2024) & (K Units)
Table 27. North America Insulin Biosimilars Sales by Country (2025-2030) & (K Units)
Table 28. North America Insulin Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Insulin Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Insulin Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Insulin Biosimilars Sales by Country (2019-2024) & (K Units)
Table 32. Europe Insulin Biosimilars Sales by Country (2025-2030) & (K Units)
Table 33. Europe Insulin Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Insulin Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Insulin Biosimilars Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Insulin Biosimilars Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Insulin Biosimilars Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Insulin Biosimilars Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Insulin Biosimilars Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Insulin Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Insulin Biosimilars Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Insulin Biosimilars Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Insulin Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Insulin Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Insulin Biosimilars Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Insulin Biosimilars Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Insulin Biosimilars Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Insulin Biosimilars Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Insulin Biosimilars Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Insulin Biosimilars Sales (K Units) by Type (2019-2024)
Table 51. Global Insulin Biosimilars Sales (K Units) by Type (2025-2030)
Table 52. Global Insulin Biosimilars Sales Market Share by Type (2019-2024)
Table 53. Global Insulin Biosimilars Sales Market Share by Type (2025-2030)
Table 54. Global Insulin Biosimilars Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Insulin Biosimilars Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Insulin Biosimilars Revenue Market Share by Type (2019-2024)
Table 57. Global Insulin Biosimilars Revenue Market Share by Type (2025-2030)
Table 58. Global Insulin Biosimilars Price (USD/Unit) by Type (2019-2024)
Table 59. Global Insulin Biosimilars Price (USD/Unit) by Type (2025-2030)
Table 60. Global Insulin Biosimilars Sales (K Units) by Application (2019-2024)
Table 61. Global Insulin Biosimilars Sales (K Units) by Application (2025-2030)
Table 62. Global Insulin Biosimilars Sales Market Share by Application (2019-2024)
Table 63. Global Insulin Biosimilars Sales Market Share by Application (2025-2030)
Table 64. Global Insulin Biosimilars Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Insulin Biosimilars Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Insulin Biosimilars Revenue Market Share by Application (2019-2024)
Table 67. Global Insulin Biosimilars Revenue Market Share by Application (2025-2030)
Table 68. Global Insulin Biosimilars Price (USD/Unit) by Application (2019-2024)
Table 69. Global Insulin Biosimilars Price (USD/Unit) by Application (2025-2030)
Table 70. Sanofi S.A. Corporation Information
Table 71. Sanofi S.A. Description and Business Overview
Table 72. Sanofi S.A. Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Sanofi S.A. Insulin Biosimilars Product
Table 74. Sanofi S.A. Recent Developments/Updates
Table 75. Boehringer Ingelheim Corporation Information
Table 76. Boehringer Ingelheim Description and Business Overview
Table 77. Boehringer Ingelheim Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Boehringer Ingelheim Insulin Biosimilars Product
Table 79. Boehringer Ingelheim Recent Developments/Updates
Table 80. Eli Lilly & Co. Corporation Information
Table 81. Eli Lilly & Co. Description and Business Overview
Table 82. Eli Lilly & Co. Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Eli Lilly & Co. Insulin Biosimilars Product
Table 84. Eli Lilly & Co. Recent Developments/Updates
Table 85. Novo Nordisk A/S Corporation Information
Table 86. Novo Nordisk A/S Description and Business Overview
Table 87. Novo Nordisk A/S Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Novo Nordisk A/S Insulin Biosimilars Product
Table 89. Novo Nordisk A/S Recent Developments/Updates
Table 90. Biocon Corporation Information
Table 91. Biocon Description and Business Overview
Table 92. Biocon Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Biocon Insulin Biosimilars Product
Table 94. Biocon Recent Developments/Updates
Table 95. Geropharm Corporation Information
Table 96. Geropharm Description and Business Overview
Table 97. Geropharm Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Geropharm Insulin Biosimilars Product
Table 99. Geropharm Recent Developments/Updates
Table 100. Wockhardt Corporation Information
Table 101. Wockhardt Description and Business Overview
Table 102. Wockhardt Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Wockhardt Insulin Biosimilars Product
Table 104. Wockhardt Recent Developments/Updates
Table 105. Gan&Lee Pharmaceuticals Corporation Information
Table 106. Gan&Lee Pharmaceuticals Description and Business Overview
Table 107. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Gan&Lee Pharmaceuticals Insulin Biosimilars Product
Table 109. Gan&Lee Pharmaceuticals Recent Developments/Updates
Table 110. The United Laboratories International Corporation Information
Table 111. The United Laboratories International Description and Business Overview
Table 112. The United Laboratories International Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. The United Laboratories International Insulin Biosimilars Product
Table 114. The United Laboratories International Recent Developments/Updates
Table 115. Tonghua Dongbao Pharmaceutical Corporation Information
Table 116. Tonghua Dongbao Pharmaceutical Description and Business Overview
Table 117. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product
Table 119. Tonghua Dongbao Pharmaceutical Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Insulin Biosimilars Distributors List
Table 123. Insulin Biosimilars Customers List
Table 124. Insulin Biosimilars Market Trends
Table 125. Insulin Biosimilars Market Drivers
Table 126. Insulin Biosimilars Market Challenges
Table 127. Insulin Biosimilars Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Insulin Biosimilars
Figure 2. Global Insulin Biosimilars Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Insulin Biosimilars Market Share by Type in 2023 & 2030
Figure 4. Rapid-Acting Biosimilars Product Picture
Figure 5. Long-Acting Biosimilars Product Picture
Figure 6. Premixed Biosimilars Product Picture
Figure 7. Global Insulin Biosimilars Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Insulin Biosimilars Market Share by Application in 2023 & 2030
Figure 9. Type I Diabetes
Figure 10. Type II Diabetes
Figure 11. Global Insulin Biosimilars Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Insulin Biosimilars Market Size (2019-2030) & (US$ Million)
Figure 13. Global Insulin Biosimilars Sales (2019-2030) & (K Units)
Figure 14. Global Insulin Biosimilars Average Price (USD/Unit) & (2019-2030)
Figure 15. Insulin Biosimilars Report Years Considered
Figure 16. Insulin Biosimilars Sales Share by Manufacturers in 2023
Figure 17. Global Insulin Biosimilars Revenue Share by Manufacturers in 2023
Figure 18. The Global 5 and 10 Largest Insulin Biosimilars Players: Market Share by Revenue in 2023
Figure 19. Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 20. Global Insulin Biosimilars Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. North America Insulin Biosimilars Sales Market Share by Country (2019-2030)
Figure 22. North America Insulin Biosimilars Revenue Market Share by Country (2019-2030)
Figure 23. United States Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Canada Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Europe Insulin Biosimilars Sales Market Share by Country (2019-2030)
Figure 26. Europe Insulin Biosimilars Revenue Market Share by Country (2019-2030)
Figure 27. Germany Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. France Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. U.K. Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Italy Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Russia Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Asia Pacific Insulin Biosimilars Sales Market Share by Region (2019-2030)
Figure 33. Asia Pacific Insulin Biosimilars Revenue Market Share by Region (2019-2030)
Figure 34. China Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Japan Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. South Korea Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. India Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Australia Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. China Taiwan Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Indonesia Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Thailand Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Malaysia Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Insulin Biosimilars Sales Market Share by Country (2019-2030)
Figure 44. Latin America Insulin Biosimilars Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Insulin Biosimilars Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Insulin Biosimilars Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE Insulin Biosimilars Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Insulin Biosimilars by Type (2019-2030)
Figure 54. Global Revenue Market Share of Insulin Biosimilars by Type (2019-2030)
Figure 55. Global Insulin Biosimilars Price (USD/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Insulin Biosimilars by Application (2019-2030)
Figure 57. Global Revenue Market Share of Insulin Biosimilars by Application (2019-2030)
Figure 58. Global Insulin Biosimilars Price (USD/Unit) by Application (2019-2030)
Figure 59. Insulin Biosimilars Value Chain
Figure 60. Insulin Biosimilars Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
